CTI Life Sciences invests in Visterra's $46.7 mln Series C

U.S. clinical-stage biotechnology company Visterra Inc has wrapped up its Series C financing, raising US$46.7 million in total. The round was backed by existing and new investors. The latter include CTI Life Sciences, a Canadian life sciences venture capital firm. Founded in 2007, Cambridge, Massachusetts-based Visterra is the creator of the Hierotope platform, which identifies unique disease targets and designs and engineers effective therapeutics. The company will use the round's proceeds to focus on its two lead product candidates and further leverage its platform.

CanadaNorth AmericaBriefs